BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

SKBBY upcoming catalysts

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: 5 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 0 FDA event(s). Subscribe to SKBBY (.ics).

Drugs: SKB264, Pembrolizumab, pemetrexed, carboplatin, Docetaxel, Eribulin, Capecitabine, Gemcitabine, Vinorelbine, Cisplatin

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06968585 A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With TrastuzumabHER2-positive Breast Canceractive not recruiting365
2026-12 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients WiNon-Small Cell Lung Canceractive not recruiting432
2026-12-30 est.P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05631262 SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsSelected Subjects With Advanced Solid Tumorsactive not recruiting321
2026-12-31 est.P1/P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05265091 A Study of KL590586 in Patients With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting414
2026-12-31 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerMetastatic Breast Cancerrecruiting376

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-Small Cell Lung Canceractive not recruiting406
2026-08 est.P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05351788 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.Non-small Cell Lung Cancerrecruiting110
2026-07-31P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05445908 SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerTriple-negative Breast Cancer and HR+/HER2- BCcompleted184

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.